The role of CD8+ and CD4+ TILs as predictive factors for anti-PD-1 therapy was evaluated in patients with NSCLC and melanoma, and an association was found between CD8+/CD4+ TIL ratios and an increased response in both cancers [170]. This evidence concerns the gene CD8A and melanoma.